NEW BIOMARKERS TO PREDICT CARDIOVASCULAR RISK IN PATIENTS WITH ADRENAL INCIDENTALOMA; IRISIN AND NESFATIN-1

Basit Öğe Kaydı
dc.contributor.authorCan, M.
dc.contributor.authorKocabas, M.
dc.contributor.authorKarakose, M.
dc.contributor.authorAlsancak, Y.
dc.contributor.authorYerlikaya, F. H.
dc.contributor.authorBurgucu, H. Caliskan
dc.contributor.authorCordan, I
dc.date.accessioned2024-02-23T14:38:01Z
dc.date.available2024-02-23T14:38:01Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjective. In our study, we aimed to investigate the levels of irisin, nesfatin-1 and the relationship between levels of these relatively new molecules with cardiometabolic risk markers; carotid intima-media thickness (CIMT), epicardial adipose tissue (EAT) thickness in patients with nonfunctional adrenal incidentaloma (NFAI). Materials and Methods. Patients with NFAI (n=59) and age, sex and body mass index-matched healthy control subjects (n=59) were enrolled in this study. Serum glucose, insulin, C-reactive protein (CRP), lipid, irisin and nesfatin-1 levels and echocardiographic CIMT and EAT thickness measurements were performed in patients and controls. Results. The irisin level was 17.58 +/- 4.38 pg/mL in the NFAI group, significantly higher (p<0.001) than 14.03 +/- 4.03 pg/mL in the control group. Nesfatin-1 level was significantly lower in the NFAI group 194.98 +/- 119.15 pg/mL ((p < 0.001)) versus 303.48 +/- 200.78 pg/mL in the control group. A positive correlation was found between irisin and nesfatin-1 levels and CIMT and EAT thickness in the NFAI group. Conclusions. In our study, we found that irisin level was higher and nesfatin-1 level was lower in patients with NFAI, and both irisin and nesfatin-1 levels were associated with CIMT and EAT thickness in NFAI patients.en_US
dc.identifier.doi10.4183/aeb.2022.150
dc.identifier.endpage155en_US
dc.identifier.issn1841-0987
dc.identifier.issn1843-066X
dc.identifier.issue2en_US
dc.identifier.pmid36212257en_US
dc.identifier.scopus2-s2.0-85139477602en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage150en_US
dc.identifier.urihttps://doi.org/10.4183/aeb.2022.150
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16336
dc.identifier.volume18en_US
dc.identifier.wosWOS:000891751400003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherEditura Acad Romaneen_US
dc.relation.ispartofActa Endocrinologica-Bucharesten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdrenal Incidentalomaen_US
dc.subjectIrisinen_US
dc.subjectNesfatin-1en_US
dc.titleNEW BIOMARKERS TO PREDICT CARDIOVASCULAR RISK IN PATIENTS WITH ADRENAL INCIDENTALOMA; IRISIN AND NESFATIN-1en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu